CRISPR-CAS9 GENE EDITING THERAPEUTICS: FROM FIRST APPROVAL TO EXPANDING CLINICAL PIPELINE. GCM. 2026;1(9):29-36. Accessed October 30, 2026. https://www.econferencia.com/index.php/5/article/view/1409